What is KeyCorp’s Estimate for GRDN Q3 Earnings?

Guardian Pharmacy Services, Inc. (NYSE:GRDN) – Analysts at KeyCorp issued their Q3 2026 EPS estimates for shares of Guardian Pharmacy Services in a report issued on Tuesday, September 22nd. KeyCorp analyst Z. Haggerty anticipates that the company will post earnings of $0.27 per share for the quarter. KeyCorp has a “Overweight” rating and a $52.00 price objective on the stock. The consensus estimate for Guardian Pharmacy Services’ current full-year earnings is $1.19 per share. KeyCorp also issued estimates for Guardian Pharmacy Services’ Q4 2026 earnings at $0.36 EPS, FY2026 earnings at $1.16 EPS, Q1 2027 earnings at $0.28 EPS, Q2 2027 earnings at $0.28 EPS, Q3 2027 earnings at $0.30 EPS, Q4 2027 earnings at $0.40 EPS, FY2027 earnings at $1.27 EPS and FY2028 earnings at $1.46 EPS.

Guardian Pharmacy Services (NYSE:GRDN) last issued its earnings results on Thursday, August 6th. The company reported $0.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.26 by $0.03. The business had revenue of $351.77 million during the quarter, compared to the consensus estimate of $340.45 million. Guardian Pharmacy Services had a net margin of 4.50% and a return on equity of 29.97%.

GRDN has been the subject of several other reports. Wall Street Zen cut Guardian Pharmacy Services from a “buy” rating to a “hold” rating in a report on Saturday, September 19th. Weiss Ratings raised Guardian Pharmacy Services from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Thursday, August 20th. Oppenheimer upped their price objective on shares of Guardian Pharmacy Services from $43.00 to $49.00 and gave the stock an “outperform” rating in a research report on Friday, August 7th. Bank of America lifted their price target on Guardian Pharmacy Services from $42.00 to $47.00 and gave the company a “buy” rating in a research note on Wednesday, June 17th. Finally, Truist Financial upped their price objective on shares of Guardian Pharmacy Services from $47.00 to $51.00 and gave the stock a “buy” rating in a research report on Monday. Nine analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, Guardian Pharmacy Services presently has a consensus rating of “Moderate Buy” and a consensus price target of $45.57.

Guardian Pharmacy Services Trading Down 3.5%

Shares of GRDN opened at $41.77 on Friday. Guardian Pharmacy Services has a 12 month low of $23.14 and a 12 month high of $48.33. The firm’s 50 day moving average is $40.76 and its 200-day moving average is $39.19. The stock has a market capitalization of $2.08 billion, a PE ratio of 40.55, a P/E/G ratio of 2.31 and a beta of 0.06.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in GRDN. Clearstead Advisors LLC grew its holdings in Guardian Pharmacy Services by 196.3% during the 4th quarter. Clearstead Advisors LLC now owns 2,628 shares of the company’s stock worth $79,000 after acquiring an additional 1,741 shares during the last quarter. Elevation Point Wealth Partners LLC acquired a new position in shares of Guardian Pharmacy Services during the first quarter worth $253,000. Stephens Inc. AR bought a new stake in shares of Guardian Pharmacy Services in the first quarter worth $282,000. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in Guardian Pharmacy Services in the second quarter valued at $335,000. Finally, Arizona State Retirement System increased its holdings in Guardian Pharmacy Services by 53.0% in the second quarter. Arizona State Retirement System now owns 8,393 shares of the company’s stock valued at $351,000 after purchasing an additional 2,907 shares during the period.

Key Guardian Pharmacy Services News

Here are the key news stories impacting Guardian Pharmacy Services this week:

• Positive Sentiment: KeyCorp initiated coverage of Guardian Pharmacy Services with an Overweight rating and a $52 price target, indicating confidence in the company’s growth prospects and potential upside. KeyBanc initiates coverage of Guardian Pharmacy Services at overweight
• Positive Sentiment: KeyCorp projected EPS of $1.27 for fiscal 2027 and $1.46 for fiscal 2028, compared with $1.16 for fiscal 2026, signaling expectations for continued earnings growth. Its quarterly forecasts range from $0.28 to $0.40 per share through 2027. Guardian Pharmacy Services Stock Rated Overweight in New Coverage at KeyCorp
• Neutral Sentiment: The multiple reports released by KeyCorp largely repeat the same rating, target price and EPS estimates rather than representing separate analyst upgrades or new company announcements. The current-year consensus EPS estimate remains $1.19.
• Negative Sentiment: KeyCorp’s $1.16 fiscal 2026 EPS forecast is modestly below the $1.19 consensus estimate, which may have tempered the market’s reaction. The stock also trades at a relatively elevated trailing P/E of about 40.6, leaving less room for disappointment even with the longer-term earnings growth outlook.

Guardian Pharmacy Services Company Profile

Guardian Pharmacy Services, Inc is a long-term care pharmacy company that provides prescription medications and related pharmacy services to residents of assisted living communities, skilled nursing facilities, memory care centers and other institutional care settings.

The company’s services include medication dispensing and packaging, prescription delivery, medication management, pharmacy consulting and clinical support. Guardian works with care providers, residents and their families to help coordinate medication regimens, improve adherence and support the ongoing pharmacy needs of patients who may require complex or recurring treatments.

Guardian Pharmacy Services operates through a network of community-based pharmacies serving long-term care customers in multiple U.S.